Pancreatic Cancer

The only top 10 cancer where survival rates are falling

Of the top 10 cancers in the UK, bladder cancer is only one where survival rates have been shown to be getting worse. New figures published this month in the Journal of Clinical Urology confirm in a study of cases of bla ...

Feb 25, 2014
popularity 4.5 / 5 (35) | comments 0

Breaking down cancer's defense mechanisms

A possible new method for treating pancreatic cancer which enables the body's immune system to attack and kill cancer cells has been developed by researchers.

Dec 20, 2013
popularity 5 / 5 (17) | comments 0 | with audio podcast

Anti-tumor activity of immune cells can be restored

The Leuven-based VIB researchers have revealed a mechanism that explains why the anti-tumor activity of specific immune cells called macrophages is suppressed during tumor growth. They have also demonstrated that blocking ...

Dec 10, 2013
popularity 5 / 5 (7) | comments 0

Major hurdle cleared to diabetes transplants

(Medical Xpress)—Researchers at Washington University School of Medicine in St. Louis have identified a way to trigger reproduction in the laboratory of clusters of human cells that make insulin, potentially ...

Jun 13, 2013
popularity 5 / 5 (4) | comments 0 | with audio podcast

Pancreatic cancer refers to a malignant neoplasm originating from transformed cells arising in tissues forming the pancreas. The most common type of pancreatic cancer, accounting for 95% of these tumors, is adenocarcinoma (tumors exhibiting glandular architecture on light microscopy) arising within the exocrine component of the pancreas. A minority arise from islet cells, and are classified as neuroendocrine tumors. The symptoms that lead to diagnosis depend on the location, the size, and the tissue type of the tumor. They may include abdominal pain and jaundice (if the tumor compresses the bile duct).

Pancreatic cancer is the fourth most common cause of cancer death across the globe. Pancreatic cancer often has a poor prognosis: for all stages combined, the 1- and 5-year relative survival rates are 25% and 6%, respectively; for local disease the 5-year survival is approximately 20% while the median survival for locally advanced and for metastatic disease, which collectively represent over 80% of individuals, is about 10 and 6 months respectively.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News